Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.
Cash Position: Cyclacel ended June 2024 with $6 million in cash and cash equivalents, up from $3.4 million at the end of 2023.
Clinical Progress: The company's lead program, fadra (an oral CDK2/9 inhibitor), is advancing in Phase II trials, with initial clinical activity data expected in Q4 2024.
Proof-of-Concept Study: Enrollment is progressing well for the Phase II proof-of-concept study targeting patients with specific chromosomal abnormalities (CDKN2A/CDKN2B).
Cost Management: R&D expenses declined significantly, with total R&D for Q2 2024 at $2 million compared to $4.7 million last year.
Runway: Management estimates current cash will fund operations into Q4 2024.
Upcoming Catalysts: Interim data from approximately a dozen patients in the enriched cohort are expected by the end of 2024.
